Table 2.

Overview of completed randomized controlled trials performed in paediatric rheumatology patients treated with bDMARDs/JAK inhibitors (July 2020)

Drug Class	Drug	Studies	Arms	Patients	Indications	Populations
Anti-CD 20 agent	rituximab	0
CD80/86 inhibitor	abatacept	1	2	190	JIA	PJIA, SJIA (without systemic features), extended OJIA
IL-1 inhibitor	anakinra	2	4	110	JIA	PJIA, SJIA
	canakinumab	2	4	261	JIA	SJIA
	rilonacept	2	5	95	JIA	SJIA
IL-6 inhibitor	sarilumab	0
	tocilizumab	3	6	356	JIA	PJIA, extended OJIA, SJIA
IL-12/23 inhibitor	ustekinumab	1	3	110	Psoriasis	Plaque psoriasis
IL-23 inhibitor	guselkumab	0
	risankizumab	0
	tildrakizumab	0
IL-17 inhibitor	brodalumab	0
	ixekizumab	1	3	201	Psoriasis	Plaque psoriasis
	secukinumab	0
TNF inhibitor	adalimumab	6	13	485	JIA, psoriasis, uveitis	ERA, JIA-associated uveitis, PJIA, plaque psoriasis
	etanercept	8	17	746	JIA, psoriasis, vasculitis	PJIA, OJIA, PsA, ERA, SJIA, plaque psoriasis, KD
	golimumab	1	2	154	JIA	PJIA, SJIA (without systemic features), PsA
	infliximab	6	13	576	JIA, uveitis, vasculitis	PJIA, non-infectious uveitis, KD
	certolizumab pegol	0
BAFF inhibitor	belimumab	1	2	93	CTD	SLE
JAK inhibitor	tofacitinib	1	2	225	JIA	ERA, PJIA, PsA
	baricitinib	0
	upadacitinib	0

Abbreviations: IL interleukin, TNF tumour necrosis factor, JAK Janus Kinase, JIA juvenile idiopathic arthritis, CTD connective tissue disease, PJIA polyarticular juvenile idiopathic arthritis, KD Kawasaki disease, SJIA systemic juvenile idiopathic arthritis, OJIA oligoarticular juvenile idiopathic arthritis, ERA enthesitis-related juvenile idiopathic arthritis, PsA psoriatic juvenile idiopathic arthritis, SLE systemic lupus erythematosus